Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

v2.4.1.9
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Operating activities:    
Net loss $ (16,542)us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax $ (372)us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 45us-gaap_Depreciation 57us-gaap_Depreciation
Stock based compensation 93us-gaap_ShareBasedCompensation 11us-gaap_ShareBasedCompensation
Fair value of warrant liabilities in excess of proceeds from financing    946us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities
Change in fair value of derivative liabilities 14,418us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet (2,106)us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
Changes in operating assets and liabilities, net of effects of reverse Merger with BiozonePharmaceuticals, Inc. and the merger with RFS Pharma, LLC:    
Prepaid expenses and other current assets (72)us-gaap_IncreaseDecreaseInPrepaidExpense (10)us-gaap_IncreaseDecreaseInPrepaidExpense
Accounts payable and accrued expenses 499us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities (306)us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
Net cash used in operating activities (1,559)us-gaap_NetCashProvidedByUsedInOperatingActivities (1,780)us-gaap_NetCashProvidedByUsedInOperatingActivities
Investing activities:    
Cash acquired in reverse merger with Biozone Pharmaceuticals, Inc.    589us-gaap_CashAcquiredFromAcquisition
Purchase of fixed assets (5)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment   
Long term deposits    (13)us-gaap_RepaymentsOfLongTermDebt
Principal payments received on mortgage notes receivable 19us-gaap_ProceedsFromSaleAndCollectionOfMortgageNotesReceivable   
Net cash provided by investing activities 14us-gaap_NetCashProvidedByUsedInInvestingActivities 576us-gaap_NetCashProvidedByUsedInInvestingActivities
Financing activities    
Proceeds from exercise of stock options 20us-gaap_ProceedsFromStockOptionsExercised 19us-gaap_ProceedsFromStockOptionsExercised
Proceeds from issuance of common stock and warrants 11,812us-gaap_ProceedsFromIssuanceOfCommonStock 2,750us-gaap_ProceedsFromIssuanceOfCommonStock
Net cash provided by financing activities 11,832us-gaap_NetCashProvidedByUsedInFinancingActivities 2,769us-gaap_NetCashProvidedByUsedInFinancingActivities
Net increase in cash and cash equivalents 10,287us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 1,565us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents at beginning of period 3,970us-gaap_CashAndCashEquivalentsAtCarryingValue 1,034us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents at end of period 14,257us-gaap_CashAndCashEquivalentsAtCarryingValue 2,599us-gaap_CashAndCashEquivalentsAtCarryingValue
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Unrealized loss on marketable securities (980)COCP_MarketableSecuritiesUnrealizedGainLossNonCash (1,451)COCP_MarketableSecuritiesUnrealizedGainLossNonCash
Estimated fair value of warrants exchanged for common shares 9,426COCP_EstimatedFairValueOfWarrantsExchangedForCommonShares   
Assets acquired and liabilities assumed in reverse Merger with Biozone Pharmaceuticals, Inc.    
Prepaid expenses and other current assets    3COCP_PrepaidExpensesAndOtherCurrentAssets
Marketable securities    8,737COCP_MarketableSecuritiesNonCash
Accounts payable and accrued expenses    410COCP_AccountsPayableAndAccruedExpenses
Derivative liabilities    $ 10,475COCP_DerivativeLiabilitiesNonCash